Avestar Capital’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$383K Buy
+7,985
New +$343K 0.02% 431
2025
Q4
Sell
-4,557
Closed -$253K 507
2025
Q3
$253K Sell
4,557
-610
-12% -$35.7K 0.02% 440
2025
Q2
$357K Buy
5,167
+334
+7% +$22.7K 0.02% 364
2025
Q1
$341K Sell
4,833
-2,219
-31% -$183K 0.03% 350
2024
Q4
$607K Sell
7,052
-146
-2% -$15.8K 0.05% 251
2024
Q3
$857K Sell
7,198
-389
-5% -$51.9K 0.09% 179
2024
Q2
$1.08M Buy
7,587
+3,196
+73% +$424K 0.11% 139
2024
Q1
$564K Buy
4,391
+3,866
+736% +$460K 0.06% 224
2023
Q4
$54.3K Buy
+525
New +$51.9K 0.01% 383
2019
Q3
Sell
-798
Closed -$18K 620
2019
Q2
$18K Hold
798
0.01% 406
2019
Q1
$20K Buy
798
+50
+7% +$1.23K 0.01% 376
2018
Q4
$15K Buy
748
+68
+10% +$1.51K 0.01% 377
2018
Q3
$13K Sell
680
-252
-27% -$6.15K 0.01% 425
2018
Q2
$18K Sell
932
-122
-12% -$2.9K 0.01% 378
2018
Q1
$24K Sell
1,054
-266
-20% -$6.98K 0.02% 310
2017
Q4
$33K Buy
+1,320
New +$33.6K 0.02% 291

Other funds holding NVO

Avestar Capital's NVO Position: Q2 2026 in Review

Avestar Capital opened a new position in Novo Nordisk (NVO) in Q2 2026: 7,985 shares worth $383K. The stake represents 0.02% of the portfolio and ranks #431 among its holdings. This is a return to the name: Avestar Capital previously reported a position in NVO as recently as Q3 2025.

Avestar Capital first reported a position in NVO in Q4 2017 and has held it in 16 quarters since. The position peaked at $1.08M in Q2 2024. 1,354 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Avestar Capital held 7,985 shares of Novo Nordisk worth $383K as of Q2 2026.
  • Novo Nordisk was a new Avestar Capital position in Q2 2026.
  • Novo Nordisk made up 0.02% of Avestar Capital's portfolio in Q2 2026, its #431 holding.
  • Avestar Capital first reported a position in Novo Nordisk in Q4 2017 and has held it in 16 quarters since.
  • Avestar Capital's Novo Nordisk position peaked at $1.08M in Q2 2024.
  • 1,354 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Avestar Capital's 13F filing for Q2 2026, filed 29 Jul 2026.